CRISPR Therapeutics is applying CRISPR-Cas9, a breakthrough gene-editing technology, to develop transformative medicines for serious diseases. CRISPR has formed the largest gene editing collaboration announced to date with Vertex Pharmaceuticals in a deal worth up to $2.6 billion. The companies have started a clinical trial in beta thalassemia. CRISPR went public in October 2016.